The Experts below are selected from a list of 2988 Experts worldwide ranked by ideXlab platform
Sabu Thomas - One of the best experts on this subject based on the ideXlab platform.
-
thermal biodegradation and theoretical perspectives on nanoscale confinement in starch cellulose nanocomposite modified via green crosslinker
International Journal of Biological Macromolecules, 2019Co-Authors: Preetha Balakrishnan, Didier Rouxel, V.g. Geethamma, Sreerag Gopi, Martin George Thomas, Matjaž Kunaver, Nandakumar Kalarikkal, Tatiana Volova, Miroslav Huskic, Sabu ThomasAbstract:In this research work, we propose a synergistic effect of a green crosslinker and cellulose nanomaterial on the crystallinity, viscoelastic, and thermal properties of starch nanocomposites. A disaccharide Derivative was used as a bio crosslinker and nanofiber from pineapple leaf as a reinforcing phase for starch. Sucrose was oxidised using periodate, that can selectively oxidise the vicinal hydroxyl group of sucrose and form tetra Aldehyde Derivative. Crystallinity of films after crosslinking decreased with successive addition of crosslinker. The melting temperature of films increased because of formation of more dense structure after crosslinking. Morphological investigations were analysed by atomic force microscopy. Polymer chain confinement and mechanics were quantified. The crosslink densities of the films were calculated using two models, phantom model and affine model, using storage modulus data. By using very low amount of crosslinker and nanoreinforcement, the properties of thermoplastic starch were significantly improved.
Fei Li - One of the best experts on this subject based on the ideXlab platform.
-
a metabolomic perspective of pazopanib induced acute hepatotoxicity in mice
Xenobiotica, 2019Co-Authors: Yikun Wang, Weiqing Liang, Xuerong Xiao, Xiaonan Yang, Yao Xiao, Frank J Gonzalez, Fei LiAbstract:AbstractTo elucidate the metabolism of pazopanib, a metabolomics approach was performed based on ultra-performance liquid chromatography coupled with electrospray ionization quadrupole mass spectrometry.A total of 22 pazopanib metabolites were identified in vitro and in vivo. Among these metabolites, 17 were novel, including several cysteine adducts and Aldehyde Derivatives. By screening using recombinant CYPs, CYP3A4 and CYP1A2 were found to be the main forms involved in the pazopanib hydroxylation. Formation of a cysteine conjugate (M3), an Aldehyde Derivative (M15) and two N-oxide metabolites (M18 and M20) from pazopanib could induce the oxidative stress that may be responsible in part for pazopanib-induced hepatotoxicity.Morphological observation of the liver suggested that pazopanib (300 mg/kg) could cause liver injury. The aspartate transaminase and alanine aminotransferase in serum significantly increased after pazopanib (150, 300 mg/kg) treatment; this liver injury could be partially reversed by t...
Preetha Balakrishnan - One of the best experts on this subject based on the ideXlab platform.
-
thermal biodegradation and theoretical perspectives on nanoscale confinement in starch cellulose nanocomposite modified via green crosslinker
International Journal of Biological Macromolecules, 2019Co-Authors: Preetha Balakrishnan, Didier Rouxel, V.g. Geethamma, Sreerag Gopi, Martin George Thomas, Matjaž Kunaver, Nandakumar Kalarikkal, Tatiana Volova, Miroslav Huskic, Sabu ThomasAbstract:In this research work, we propose a synergistic effect of a green crosslinker and cellulose nanomaterial on the crystallinity, viscoelastic, and thermal properties of starch nanocomposites. A disaccharide Derivative was used as a bio crosslinker and nanofiber from pineapple leaf as a reinforcing phase for starch. Sucrose was oxidised using periodate, that can selectively oxidise the vicinal hydroxyl group of sucrose and form tetra Aldehyde Derivative. Crystallinity of films after crosslinking decreased with successive addition of crosslinker. The melting temperature of films increased because of formation of more dense structure after crosslinking. Morphological investigations were analysed by atomic force microscopy. Polymer chain confinement and mechanics were quantified. The crosslink densities of the films were calculated using two models, phantom model and affine model, using storage modulus data. By using very low amount of crosslinker and nanoreinforcement, the properties of thermoplastic starch were significantly improved.
Yikun Wang - One of the best experts on this subject based on the ideXlab platform.
-
a metabolomic perspective of pazopanib induced acute hepatotoxicity in mice
Xenobiotica, 2019Co-Authors: Yikun Wang, Weiqing Liang, Xuerong Xiao, Xiaonan Yang, Yao Xiao, Frank J Gonzalez, Fei LiAbstract:AbstractTo elucidate the metabolism of pazopanib, a metabolomics approach was performed based on ultra-performance liquid chromatography coupled with electrospray ionization quadrupole mass spectrometry.A total of 22 pazopanib metabolites were identified in vitro and in vivo. Among these metabolites, 17 were novel, including several cysteine adducts and Aldehyde Derivatives. By screening using recombinant CYPs, CYP3A4 and CYP1A2 were found to be the main forms involved in the pazopanib hydroxylation. Formation of a cysteine conjugate (M3), an Aldehyde Derivative (M15) and two N-oxide metabolites (M18 and M20) from pazopanib could induce the oxidative stress that may be responsible in part for pazopanib-induced hepatotoxicity.Morphological observation of the liver suggested that pazopanib (300 mg/kg) could cause liver injury. The aspartate transaminase and alanine aminotransferase in serum significantly increased after pazopanib (150, 300 mg/kg) treatment; this liver injury could be partially reversed by t...
-
A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice
2018Co-Authors: Yikun Wang, Weiqing Liang, Xuerong Xiao, Xiaonan Yang, Yao Xiao, Qi Zhao, Frank J GonzalezAbstract:To elucidate the metabolism of pazopanib, a metabolomics approach was performed based on ultra-performance liquid chromatography coupled with electrospray ionization quadrupole mass spectrometry.A total of 22 pazopanib metabolites were identified in vitro and in vivo. Among these metabolites, 17 were novel, including several cysteine adducts and Aldehyde Derivatives. By screening using recombinant CYPs, CYP3A4 and CYP1A2 were found to be the main forms involved in the pazopanib hydroxylation. Formation of a cysteine conjugate (M3), an Aldehyde Derivative (M15) and two N-oxide metabolites (M18 and M20) from pazopanib could induce the oxidative stress that may be responsible in part for pazopanib-induced hepatotoxicity.Morphological observation of the liver suggested that pazopanib (300 mg/kg) could cause liver injury. The aspartate transaminase and alanine aminotransferase in serum significantly increased after pazopanib (150, 300 mg/kg) treatment; this liver injury could be partially reversed by the broad-spectrum CYP inhibitor 1-aminobenzotriazole (ABT). Metabolomics analysis revealed that pazopanib could significantly change the levels of L-carnitine, proline and lysophosphatidylcholine 18:1 in liver. Additionally, drug metabolism-related gene expression analysis revealed that hepatic Cyp2d22 and Abcb1a (P-gp) mRNAs were significantly lowered by pazopanib treatment.In conclusion, this study provides a global view of pazopanib metabolism and clues to its influence on hepatic function. To elucidate the metabolism of pazopanib, a metabolomics approach was performed based on ultra-performance liquid chromatography coupled with electrospray ionization quadrupole mass spectrometry. A total of 22 pazopanib metabolites were identified in vitro and in vivo. Among these metabolites, 17 were novel, including several cysteine adducts and Aldehyde Derivatives. By screening using recombinant CYPs, CYP3A4 and CYP1A2 were found to be the main forms involved in the pazopanib hydroxylation. Formation of a cysteine conjugate (M3), an Aldehyde Derivative (M15) and two N-oxide metabolites (M18 and M20) from pazopanib could induce the oxidative stress that may be responsible in part for pazopanib-induced hepatotoxicity. Morphological observation of the liver suggested that pazopanib (300 mg/kg) could cause liver injury. The aspartate transaminase and alanine aminotransferase in serum significantly increased after pazopanib (150, 300 mg/kg) treatment; this liver injury could be partially reversed by the broad-spectrum CYP inhibitor 1-aminobenzotriazole (ABT). Metabolomics analysis revealed that pazopanib could significantly change the levels of L-carnitine, proline and lysophosphatidylcholine 18:1 in liver. Additionally, drug metabolism-related gene expression analysis revealed that hepatic Cyp2d22 and Abcb1a (P-gp) mRNAs were significantly lowered by pazopanib treatment. In conclusion, this study provides a global view of pazopanib metabolism and clues to its influence on hepatic function.
Frank J Gonzalez - One of the best experts on this subject based on the ideXlab platform.
-
a metabolomic perspective of pazopanib induced acute hepatotoxicity in mice
Xenobiotica, 2019Co-Authors: Yikun Wang, Weiqing Liang, Xuerong Xiao, Xiaonan Yang, Yao Xiao, Frank J Gonzalez, Fei LiAbstract:AbstractTo elucidate the metabolism of pazopanib, a metabolomics approach was performed based on ultra-performance liquid chromatography coupled with electrospray ionization quadrupole mass spectrometry.A total of 22 pazopanib metabolites were identified in vitro and in vivo. Among these metabolites, 17 were novel, including several cysteine adducts and Aldehyde Derivatives. By screening using recombinant CYPs, CYP3A4 and CYP1A2 were found to be the main forms involved in the pazopanib hydroxylation. Formation of a cysteine conjugate (M3), an Aldehyde Derivative (M15) and two N-oxide metabolites (M18 and M20) from pazopanib could induce the oxidative stress that may be responsible in part for pazopanib-induced hepatotoxicity.Morphological observation of the liver suggested that pazopanib (300 mg/kg) could cause liver injury. The aspartate transaminase and alanine aminotransferase in serum significantly increased after pazopanib (150, 300 mg/kg) treatment; this liver injury could be partially reversed by t...
-
A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice
2018Co-Authors: Yikun Wang, Weiqing Liang, Xuerong Xiao, Xiaonan Yang, Yao Xiao, Qi Zhao, Frank J GonzalezAbstract:To elucidate the metabolism of pazopanib, a metabolomics approach was performed based on ultra-performance liquid chromatography coupled with electrospray ionization quadrupole mass spectrometry.A total of 22 pazopanib metabolites were identified in vitro and in vivo. Among these metabolites, 17 were novel, including several cysteine adducts and Aldehyde Derivatives. By screening using recombinant CYPs, CYP3A4 and CYP1A2 were found to be the main forms involved in the pazopanib hydroxylation. Formation of a cysteine conjugate (M3), an Aldehyde Derivative (M15) and two N-oxide metabolites (M18 and M20) from pazopanib could induce the oxidative stress that may be responsible in part for pazopanib-induced hepatotoxicity.Morphological observation of the liver suggested that pazopanib (300 mg/kg) could cause liver injury. The aspartate transaminase and alanine aminotransferase in serum significantly increased after pazopanib (150, 300 mg/kg) treatment; this liver injury could be partially reversed by the broad-spectrum CYP inhibitor 1-aminobenzotriazole (ABT). Metabolomics analysis revealed that pazopanib could significantly change the levels of L-carnitine, proline and lysophosphatidylcholine 18:1 in liver. Additionally, drug metabolism-related gene expression analysis revealed that hepatic Cyp2d22 and Abcb1a (P-gp) mRNAs were significantly lowered by pazopanib treatment.In conclusion, this study provides a global view of pazopanib metabolism and clues to its influence on hepatic function. To elucidate the metabolism of pazopanib, a metabolomics approach was performed based on ultra-performance liquid chromatography coupled with electrospray ionization quadrupole mass spectrometry. A total of 22 pazopanib metabolites were identified in vitro and in vivo. Among these metabolites, 17 were novel, including several cysteine adducts and Aldehyde Derivatives. By screening using recombinant CYPs, CYP3A4 and CYP1A2 were found to be the main forms involved in the pazopanib hydroxylation. Formation of a cysteine conjugate (M3), an Aldehyde Derivative (M15) and two N-oxide metabolites (M18 and M20) from pazopanib could induce the oxidative stress that may be responsible in part for pazopanib-induced hepatotoxicity. Morphological observation of the liver suggested that pazopanib (300 mg/kg) could cause liver injury. The aspartate transaminase and alanine aminotransferase in serum significantly increased after pazopanib (150, 300 mg/kg) treatment; this liver injury could be partially reversed by the broad-spectrum CYP inhibitor 1-aminobenzotriazole (ABT). Metabolomics analysis revealed that pazopanib could significantly change the levels of L-carnitine, proline and lysophosphatidylcholine 18:1 in liver. Additionally, drug metabolism-related gene expression analysis revealed that hepatic Cyp2d22 and Abcb1a (P-gp) mRNAs were significantly lowered by pazopanib treatment. In conclusion, this study provides a global view of pazopanib metabolism and clues to its influence on hepatic function.